RecruitingEarly Phase 1NCT06066710

Propranolol in Primary Progressive Aphasia

Trial of Propranolol in Older Adults with Primary Progressive Aphasia


Sponsor

University of Missouri-Columbia

Enrollment

30 participants

Start Date

Jan 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.


Eligibility

Min Age: 50 Years

Inclusion Criteria3

  • \. Age: 50 and older
  • \. Primary Progressive Aphasia diagnosis
  • \. Native English speaker

Exclusion Criteria14

  • \. Unable to provide consent
  • \. Taking alpha 2 agonists (clonidine and guanfacine)
  • \. Other major psychological or neurological diagnosis
  • \. Major head trauma that contributed to their condition
  • \. Allergic reaction to adhesives
  • \. Uncorrected vision/hearing impairments
  • \. Diabetes
  • \. Reactive airway disease
  • \. Untreated hypothyroidism
  • \. Bradyarrhythmia
  • \. Unexplained syncope
  • \. Pregnancy (assessed verbally on the days of MR imaging)
  • \. Drugs that interact with propranolol, such as alpha 2 agonists
  • \. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPropranolol

Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.

DEVICEMagnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.

DRUGPlacebo

Placebo will be given on the same schedule as the propranolol regime.


Locations(1)

University of Missouri-Columbia

Columbia, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06066710


Related Trials